title: [Evaluation of the S-1 granule forms in gastric cancer patients who received treatment with S-1 capsule-questionnaire survey about drug dosage forms].
abstract: The S-1(tegafur/gimeracil/oteracil potassium)granule was developed to meet the needs of patients with cancer. Although the choice of the patients was thought to spread by the addition of the new agent type, the recognition of the S-1 granule is still low and you should adapt yourself to what kind of patients or are unknown. Therefore, we conducted a questionnaire survey of patients with gastric cancer undergoing treatment with S-1 capsules to investigate the adaptation and taste of the patients. As a result, although it was the investigation by the patients during S-1 capsule remedy, it was replied when 21. 3%(13/61 case)'had good granule,'and all cases raised it by the reason of there'not being the sense of incongruity of the throat at taking.'Also, about the global assessment of granule, the proportion of patient who replied'very good'or'good'were 31. 1% and 47%, in all cases and in the cases that felt the sense of incongruity of the throat during S-1 capsule remedy, respectively. Therefore, in the patients treated with the S-1 capsule, there were thought to be the patients who expected treatment with a granule. By the results of this survey, it was found that it is necessary to perform a medical teaching including dosage form to contribute to the adherence improvement of the patients.
authors.affiliation: Pharmaceutical Department, Sakai Municipal Hospital.
authors.forename: Misako
authors.initials: M
authors.lastname: Fujino
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Rumi
authors.initials: R
authors.lastname: Sumida
authors.forename: Setsuko
authors.initials: S
authors.lastname: Anami
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Hachino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D002214:Capsules; D003679:Deglutition; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D011208:Powders; D013274:Stomach Neoplasms / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D005641:Tegafur / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D002214:Capsules; D004338:Drug Combinations; D011208:Powders; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid